EuroNet-PHL-LP1: complete resection or low-dose chemotherapy for pediatric low-risk nodular lymphocyte-predominant Hodgkin lymphoma.
Ananth Shankar, Judith Landman-Parker, Maurizio Mascarin et al.
✦ AI-curated · Sources linked
In 30 seconds
The EuroNet-PHL-LP1 trial evaluated treatment strategies for pediatric patients with early-stage nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL). In this phase 3 trial involving patients under 18 years, those undergoing complete resection had a 5-year event-free survival (EFS) of 79.5%. Patients receiving low-intensity CVP chemotherapy had a 5-year EFS of 56.4%, with 91.3% EFS in those achieving complete metabolic response.
Key findings
- 5-year EFS for patients undergoing complete resection was 79.5%.
- In CVP cohort 1, 5-year EFS was 56.4%, with 91.3% EFS in those achieving complete metabolic response.
- PFS in CVP cohort 2 was 64.7%.
- 68.3% of patients experienced grade 3 to 4 neutropenia during CVP treatment.
Why it matters
This study provides evidence that both complete surgical resection and low-intensity chemotherapy can yield favorable outcomes in pediatric nLPHL, potentially guiding treatment decisions and improving patient management strategies.